% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Palleis:904371,
      author       = {Palleis, Carla and Brendel, Matthias and Finze, Anika and
                      Weidinger, Endy and Bötzel, Kai and Danek, Adrian and
                      Beyer, Leonie and Nitschmann, Alexander and Kern, Maike and
                      Biechele, Gloria and Rauchmann, Boris-Stephan and Häckert,
                      Jan and Höllerhage, Matthias and Stephens, Andrew W. and
                      Drzezga, Alexander and Eimeren, Thilo and Villemagne, Victor
                      L. and Schildan, Andreas and Barthel, Henryk and Patt,
                      Marianne and Sabri, Osama and Bartenstein, Peter and
                      Perneczky, Robert and Haass, Christian and Levin, Johannes
                      and Höglinger, Günter U.},
      title        = {{C}ortical [18{F}]{PI}‐2620 {B}inding {D}ifferentiates
                      {C}orticobasal {S}yndrome {S}ubtypes},
      journal      = {Movement disorders},
      volume       = {36},
      number       = {9},
      issn         = {0885-3185},
      address      = {New York, NY},
      publisher    = {Wiley},
      reportid     = {FZJ-2021-05941},
      pages        = {2104 - 2115},
      year         = {2021},
      abstract     = {Background: Corticobasal syndrome is associated with
                      cerebral protein aggregates composed of 4-repeat $(~50\%$ of
                      cases) or mixed 3-repeat/4-repeat tau isoforms $(~25\%$ of
                      cases) or nontauopathies $(~25\%$ of cases).Objectives: The
                      aim of this single-center study was to investigate the
                      diagnostic value of the tau PET-ligand [18 F]PI-2620 in
                      patients with corticobasal syndrome.Methods: Forty-five
                      patients (71.5 ± 7.6 years) with corticobasal syndrome and
                      14 age-matched healthy controls underwent [18 F]PI-2620-PET.
                      Beta-amyloid status was determined by cerebral β-amyloid
                      PET and/or CSF analysis. Subcortical and cortical [18
                      F]PI-2620 binding was quantitatively and visually compared
                      between β-amyloid-positive and -negative patients and
                      controls. Regional [18 F]PI-2620 binding was correlated with
                      clinical and demographic data.Results: Twenty-four percent
                      (11 of 45) were β-amyloid-positive. Significantly elevated
                      [18 F]PI-2620 distribution volume ratios were observed in
                      both β-amyloid-positive and β-amyloid-negative patients
                      versus controls in the dorsolateral prefrontal cortex and
                      basal ganglia. Cortical [18 F]PI-2620 PET positivity was
                      distinctly higher in β-amyloid-positive compared with
                      β-amyloid-negative patients with pronounced involvement of
                      the dorsolateral prefrontal cortex. Semiquantitative
                      analysis of [18 F]PI-2620 PET revealed a sensitivity of
                      $91\%$ for β-amyloid-positive and of $65\%$ for
                      β-amyloid-negative cases, which is in excellent agreement
                      with prior clinicopathological data. Regardless of
                      β-amyloid status, hemispheric lateralization of [18
                      F]PI-2620 signal reflected contralateral predominance of
                      clinical disease severity.Conclusions: Our data indicate a
                      value of [18 F]PI-2620 for evaluating corticobasal syndrome,
                      providing quantitatively and regionally distinct signals in
                      β-amyloid-positive as well as β-amyloid-negative
                      corticobasal syndrome. In corticobasal syndrome, [18
                      F]PI-2620 may potentially serve for a differential diagnosis
                      and for monitoring disease progression. © 2021 The Authors.
                      Movement Disorders published by Wiley Periodicals LLC on
                      behalf of International Parkinson and Movement Disorder
                      Society.Keywords: Alzheimer's disease; PET; corticobasal
                      syndrome; four-repeat tauopathies; tau.},
      cin          = {INM-2},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-2-20090406},
      pnm          = {5253 - Neuroimaging (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {33951244},
      UT           = {WOS:000647195800001},
      doi          = {10.1002/mds.28624},
      url          = {https://juser.fz-juelich.de/record/904371},
}